Ropivacaine Hydrochloride
Loading...Ropivacaine Hydrochloride Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
In performing ropivacaine hydrochloride blocks, unintended intravenous injection is possible and may result in cardiac arrhythmia or cardiac arrest. The potential for successful resuscitation has not been studied in humans. There have been rare reports of cardiac arrest during the use of ropivacaine hydrochloride for epidural anesthesia or peripheral nerve blockade, the majority of which occurred after unintentional accidental intravascular administration in elderly patients and in patients with concomitant heart disease. In some instances, resuscitation has been difficult. Should cardiac arrest occur, prolonged resuscitative efforts may be required to improve the probability of a successful outcome.
Ropivacaine hydrochloride should be administered in incremental doses. It is not recommended for emergency situations, where a fast onset of surgical anesthesia is necessary. Historically, pregnant patients were reported to have a high risk for cardiac arrhythmias, cardiac/circulatory arrest and death when 0.75% bupivacaine (another member of the amino amide class of local anesthetics) was inadvertently rapidly injected intravenously.
Prior to receiving major blocks the general condition of the patient should be optimized and the patient should have an IV line inserted. All necessary precautions should be taken to avoid intravascular injection. Local anesthetics should only be administered by clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate (without delay) availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies (see also ADVERSE REACTIONS, PRECAUTIONS and MANAGEMENT OF LOCAL ANESTHETIC EMERGENCIES). Delay in proper management of dose-related toxicity, under ventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. Solutions of ropivacaine hydrochloride should not be used for the production of obstetrical paracervical block anesthesia, retrobulbar block, or spinal anesthesia (subarachnoid block) due to insufficient data to support such use. Intravenous regional anesthesia (bier block) should not be performed due to a lack of clinical experience and the risk of attaining toxic blood levels of ropivacaine.
Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.
It is essential that aspiration for blood, or cerebrospinal fluid (where applicable), be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative aspiration does not ensure against an intravascular or subarachnoid injection.
A well-known risk of epidural anesthesia may be an unintentional subarachnoid injection of local anesthetic. Two clinical studies have been performed to verify the safety of ropivacaine hydrochloride at a volume of 3 mL injected into the subarachnoid space since this dose represents an incremental epidural volume that could be unintentionally injected. The 15 and 22.5 mg doses injected resulted in sensory levels as high as T5 and T4, respectively. Anesthesia to pinprick started in the sacral dermatomes in 2 to 3 minutes, extended to the T10 level in 10 to 13 minutes and lasted for approximately 2 hours. The results of these two clinical studies showed that a 3 mL dose did not produce any serious adverse events when spinal anesthesia blockade was achieved.
Ropivacaine hydrochloride should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.
Patients treated with class III antiarrhythmic drugs (eg, amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Ropivacaine Hydrochloride Injection is indicated for the production of local or regional anesthesia for surgery and for acute pain management.
Surgical Anesthesia: epidural block for surgery including cesarean section; major nerve block; local infiltration
Acute Pain Management: epidural continuous infusion or intermittent bolus, eg, postoperative or labor; local infiltration
History
There is currently no drug history available for this drug.
Other Information
Ropivacaine Hydrochloride Injection, USP contains ropivacaine hydrochloride which is a member of the amino amide class of local anesthetics. Ropivacaine Hydrochloride Injection, USP is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride, USP for isotonicity and Water for Injection, USP. Sodium hydroxide, NF and/or hydrochloric acid, NF may be used for pH adjustment. It is administered parenterally.
Ropivacaine HCl is chemically described as S-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride. The drug substance is a white crystalline powder, with a molecular formula of C17H26N2O•HCl, molecular weight of 310.87 and the following structural formula:
At 25°C ropivacaine HCl has a solubility of 53.8 mg/mL in water, a distribution ratio between n-octanol and phosphate buffer at pH 7.4 of 14:1 and a pKa of 8.07 in 0.1 M KCl solution. The pKa of ropivacaine is approximately the same as bupivacaine (8.1) and is similar to that of mepivacaine (7.7). However, ropivacaine has an intermediate degree of lipid solubility compared to bupivacaine and mepivacaine.
Ropivacaine Hydrochloride Injection, USP is preservative-free and is available in single dose containers in 5 mg/mL (0.5%) and 10 mg/mL (1%) concentrations. The specific gravity of Ropivacaine Hydrochloride Injection, USP solutions range from 1.002 to 1.005 at 25°C.
Sources
Ropivacaine Hydrochloride Manufacturers
-
Sandoz Inc
![Ropivacaine Hydrochloride Injection, Solution [Sandoz Inc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Ropivacaine Hydrochloride | Sandoz Inc
The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should always be used. The smallest dose and concentration required to produce the desired result should be administered.
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Ropivacaine hydrochloride injection is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION).
The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Patients in poor general condition due to aging or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention although regional anesthesia is frequently indicated in these patients. To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed, and the dosage should be adjusted accordingly.
Use an adequate test dose (3 to 5 mL of a short-acting local anesthetic solution containing epinephrine) prior to induction of complete block. This test dose should be repeated if the patient is moved in such a fashion as to have displaced the epidural catheter. Allow adequate time for onset of anesthesia following administration of each test dose.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions which are discolored or which contain particulate matter should not be administered.
Table 7 Dosage Recommendations * = Not Applicable † = The dose for a major nerve block must be adjusted according to site of administration and patient status. Supraclavicular brachial plexus blocks may be associated with a higher frequency of serious adverse reactions, regardless of the local anesthetic used (see PRECAUTIONS). ‡ = Median dose of 21 mg per hour was administered by continuous infusion or by incremental injections (top-ups) over a median delivery time of 5.5 hours. § = Cumulative doses up to 770 mg of ropivacaine hydrochloride over 24 hours (intraoperative block plus postoperative infusion); Continuous epidural infusion at rates up to 28 mg per hour for 72 hours have been well tolerated in adults, ie, 2016 mg plus surgical dose of approximately 100 to 150 mg as top-up.
Conc.
Volume
Dose
Onset
Duration
mg/mL
(%)
mL
mg
min
hours
SURGICAL ANESTHESIA
Lumbar Epidural
5
(0.5%)
15 to 30
75 to 150
15 to 30
2 to 4
Administration
7.5
(0.75%)
15 to 25
113 to 188
10 to 20
3 to 5
Surgery
10
(1%)
15 to 20
150 to 200
10 to 20
4 to 6
Lumbar Epidural
5
(0.5%)
20 to 30
100 to 150
15 to 25
2 to 4
Administration
7.5
(0.75%)
15 to 20
113 to 150
10 to 20
3 to 5
Cesarean Section
Thoracic Epidural
5
(0.5%)
5 to 15
25 to 75
10 to 20
n/a*
Administration
7.5
(0.75%)
5 to 15
38 to 113
10 to 20
n/a*
Surgery
Major Nerve Block†
5
(0.5%)
35 to 50
175 to 250
15 to 30
5 to 8
(eg, brachial plexus block)
7.5
(0.75%)
10 to 40
75 to 300
10 to 25
6 to 10
Field Block(eg, minor nerve block and infiltration)
5
(0.5%)
1 to 40
5 to 200
1 to 15
2 to 6
LABOR PAIN MANAGEMENT
Lumbar Epidural Administration
Initial Dose
2
(0.2%)
10 to 20
20 to 40
10 to 15
0.5 to 1.5
Continuous infusion‡
2
(0.2%)
6 to 14
mL/h
12 to 28
mg/h
n/a*
n/a*
Incremental
injections (top-up)‡
2
(0.2%)
10 to 15
mL/h
20 to 30
mg/h
n/a*
n/a*
POSTOPERATIVE PAIN MANAGEMENT
Lumbar Epidural Administration
Continuous infusion§
2
(0.2%)
6 to 14
mL/h
12 to 28
mg/h
n/a*
n/a*
Thoracic Epidural
Administration
2
(0.2%)
6 to 14
mL/h
12 to 28
mg/h
n/a*
n/a*
Continuous infusion§
Infiltration
2
(0.2%)
1 to 100
2 to 200
1 to 5
2 to 6
(eg, minor nerve block)
5
(0.5%)
1 to 40
5 to 200
1 to 5
2 to 6
The doses in the table are those considered to be necessary to produce a successful block and should be regarded as guidelines for use in adults. Individual variations in onset and duration occur. The figures reflect the expected average dose range needed. For other local anesthetic techniques standard current textbooks should be consulted.
When prolonged blocks are used, either through continuous infusion or through repeated bolus administration, the risks of reaching a toxic plasma concentration or inducing local neural injury must be considered. Experience to date indicates that a cumulative dose of up to 770 mg ropivacaine hydrochloride administered over 24 hours is well tolerated in adults when used for postoperative pain management: ie, 2016 mg. Caution should be exercised when administering ropivacaine hydrochloride for prolonged periods of time, eg, >70 hours in debilitated patients.
For treatment of postoperative pain, the following technique can be recommended: If regional anesthesia was not used intraoperatively, then an initial epidural block with 5 to 7 mL ropivacaine hydrochloride is induced via an epidural catheter. Analgesia is maintained with an infusion of ropivacaine hydrochloride, 2 mg/mL (0.2%). Clinical studies have demonstrated that infusion rates of 6 to 14 mL (12 to 28 mg) per hour provide adequate analgesia with nonprogressive motor block. With this technique a significant reduction in the need for opioids was demonstrated. Clinical experience supports the use of ropivacaine hydrochloride epidural infusions for up to 72 hours.
-
Sagent Pharmaceuticals
Ropivacaine Hydrochloride | Sagent Pharmaceuticals
The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should always be used. The smallest dose and concentration required to produce the desired result should be administered.
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Ropivacaine hydrochloride is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION).
The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Patients in poor general condition due to aging or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention although regional anesthesia is frequently indicated in these patients. To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed, and the dosage should be adjusted accordingly.
Use an adequate test dose (3 mL to 5 mL of a short acting local anesthetic solution containing epinephrine) prior to induction of complete block. This test dose should be repeated if the patient is moved in such a fashion as to have displaced the epidural catheter. Allow adequate time for onset of anesthesia following administration of each test dose.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions which are discolored or which contain particulate matter should not be administered.
Table 7 Dosage Recommendations* Not Applicable
† The dose for a major nerve block must be adjusted according to site of administration and patient status. Supraclavicular brachial plexus blocks may be associated with a higher frequency of serious adverse reactions, regardless of the local anesthetic used (see PRECAUTIONS).
‡ Median dose of 21 mg per hour was administered by continuous infusion or by incremental injections (top-ups) over a median delivery time of 5.5 hours.
§ Cumulative doses up to 770 mg of ropivacaine hydrochloride over 24 hours (intraoperative block plus postoperative infusion); Continuous epidural infusion at rates up to 28 mg per hour for 72 hours have been well tolerated in adults, i.e., 2016 mg plus surgical dose of approximately 100 mg to 150 mg as top-up.
Conc. Volume
mL Dose
mg Onset min Duration hours mg/mL (%) SURGICAL ANESTHESIA Lumbar Epidural 5 (0.5%) 15 to 30 75 to 150 15 to 30 2 to 4 Administration 7.5 (0.75%) 15 to 25 113 to 188 10 to 20 3 to 5 Surgery 10 (1%) 15 to 20 150 to 200 10 to 20 4 to 6 Lumbar Epidural 5 (0.5%) 20 to 30 100 to 150 15 to 25 2 to 4 Administration 7.5 (0.75%) 15 to 20 113 to 150 10 to 20 3 to 5 Cesarean Section Thoracic Epidural 5 (0.5%) 5 to 15 25 to 75 10 to 20 n/a* Administration 7.5 (0.75%) 5 to 15 38 to 113 10 to 20 n/a* Surgery Major Nerve Block† 5 (0.5%) 35 to 50 175 to 250 15 to 30 5 to 8 (e.g., brachial plexus block) 7.5 (0.75%) 10 to 40 75 to 300 10 to 25 6 to 10 Field Block 5 (0.5%) 1 to 40 5 to 200 1 to 15 2 to 6 (e.g., minor nerve blocks
and infiltration) LABOR PAIN MANAGEMENT Lumbar Epidural Administration Initial Dose 2 (0.2%) 10 to 20 20 to 40 10 to 15 0.5 to 1.5 Continuous infusion‡ 2 (0.2%) 6 to 14 mL/h 12 to 28 mg/h n/a* n/a* Incremental injections (top-up)‡ 2 (0.2%) 10 to 15 mL/h 20 to 30 mg/h n/a* n/a* POSTOPERATIVE PAIN MANAGEMENT Lumbar Epidural Administration Continuous infusion§ 2 (0.2%) 6 to 14 mL/h 12 to 28 mg/h n/a* n/a* Thoracic Epidural Administration 2 (0.2%) 6 to 14 mL/h 12 to 28 mg/h n/a* n/a* Continuous infusion§ Infiltration
(e.g., minor nerve block) 2
5 (0.2%)
(0.5%) 1 to 100
1 to 40 2 to 200
5 to 200 1 to 5
1 to 5 2 to 6
2 to 6The doses in the table are those considered to be necessary to produce a successful block and should be regarded as guidelines for use in adults. Individual variations in onset and duration occur. The figures reflect the expected average dose range needed. For other local anesthetic techniques standard current textbooks should be consulted.
When prolonged blocks are used, either through continuous infusion or through repeated bolus administration, the risks of reaching a toxic plasma concentration or inducing local neural injury must be considered. Experience to date indicates that a cumulative dose of up to 770 mg ropivacaine hydrochloride administered over 24 hours is well tolerated in adults when used for postoperative pain management: i.e., 2016 mg. Caution should be exercised when administering ropivacaine hydrochloride for prolonged periods of time, e.g., > 70 hours in debilitated patients.
For treatment of postoperative pain, the following technique can be recommended: If regional anesthesia was not used intraoperatively, then an initial epidural block with 5 mL to 7 mL ropivacaine hydrochloride is induced via an epidural catheter. Analgesia is maintained with an infusion of ropivacaine hydrochloride, 2 mg/mL (0.2%). Clinical studies have demonstrated that infusion rates of 6 mL to 14 mL (12 mg to 28 mg) per hour provide adequate analgesia with nonprogressive motor block. With this technique a significant reduction in the need for opioids was demonstrated. Clinical experience supports the use of ropivacaine hydrochloride epidural infusions for up to 72 hours.
-
Hospira, Inc.
Ropivacaine Hydrochloride | Hospira, Inc.
The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should always be used. The smallest dose and concentration required to produce the desired result should be administered.
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Ropivacaine is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION).
The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Patients in poor general condition due to aging or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention although regional anesthesia is frequently indicated in these patients. To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed, and the dosage should be adjusted accordingly.
Use an adequate test dose (3 mL to 5 mL of a short acting local anesthetic solution containing epinephrine) prior to induction of complete block. This test dose should be repeated if the patient is moved in such a fashion as to have displaced the epidural catheter. Allow adequate time for onset of anesthesia following administration of each test dose.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions that are discolored or that contain particulate matter should not be administered.
Table 7 DOSAGE RECOMMENDATIONS * = Not Applicable
† = The dose for a major nerve block must be adjusted according to site of administration and patient status. Supraclavicular brachial plexus blocks may be associated with a higher frequency of serious adverse reactions, regardless of the local anesthetic used (see PRECAUTIONS).
‡ = Median dose of 21 mg per hour was administered by continuous infusion or by incremental injections (top-ups) over a median delivery time of 5.5 hours.
§ = Cumulative doses up to 770 mg of ropivacaine HCl; over 24 hours (intraoperative block plus postoperative infusion); Continuous epidural infusion at rates up to 28 mg per hour for 72 hours have been well tolerated in adults, ie, 2016 mg plus surgical dose of approximately 100 mg to 150 mg as top-up.Conc.
Volume
mL
Dose
mg
Onset
min
Duration
hours
mg/mL
(%)
SURGICAL ANESTHESIA
Lumbar Epidural
Administration
Surgery
5
7.5
10
(0.5%)
(0.75%)
(1%)
15 to 30
15 to 25
15 to 20
75 to 150
113 to 188
150 to 200
15 to 30
10 to 20
10 to 20
2 to 4
3 to 5
4 to 6
Lumbar Epidural
Administration
Cesarean Section
5
7.5
(0.5%)
(0.75%)
20 to 30
15 to 20
100 to 150
113 to 150
15 to 25
10 to 20
2 to 4
3 to 5
Thoracic Epidural
Administration
Surgery
5
7.5
(0.5%)
(0.75%)
5 to 15
5 to 15
25 to 75
38 to 113
10 to 20
10 to 20
n/a*
n/a*
Major Nerve Block†
(eg brachial plexus block)
5
7.5
(0.5%)
(0.75%)
35 to 50
10 to 40
175 to 250
75 to 300
15 to 30
10 to 25
5 to 8
6 to 10
Field Block
(eg minor nerve blocks and infiltration)
5
(0.5%)
1 to 40
5 to 200
1 to 15
2 to 6
LABOR PAIN MANAGEMENT
Lumbar Epidural Administration
Initial Dose
2
(0.2%)
10 to 20
20 to 40
10 to 15
0.5 to 1.5
Continuous infusion‡
2
(0.2%)
6 to 14 mL/h
12 to 28 mg/h
n/a*
n/a*
Incremental injections (top-up)‡
2
(0.2%)
10 to 15 mL/h
20 to 30 mg/h
n/a*
n/a*
POSTOPERATIVE PAIN MANAGEMENT
Lumbar Epidural Administration
Continuous infusion§
2
(0.2%)
6 to 14 mL/h
12 to 28 mg/h
n/a*
n/a*
Thoracic Epidural Administration
Continuous infusion§
2
(0.2%)
6 to 14 mL/h
12 to 28 mg/h
n/a*
n/a*
Infiltration
2
(0.2%)
1 to 100
2 to 200
1 to 5
2 to 6
(eg, minor nerve block)
5
(0.5%)
1 to 40
5 to 200
1 to 5
2 to 6
The doses in the table are those considered to be necessary to produce a successful block and should be regarded as guidelines for use in adults. Individual variations in onset and duration occur. The figures reflect the expected average dose range needed. For other local anesthetic techniques standard current textbooks should be consulted.
When prolonged blocks are used, either through continuous infusion or through repeated bolus administration, the risks of reaching a toxic plasma concentration or inducing local neural injury must be considered. Experience to date indicates that a cumulative dose of up to 770 mg ropivacaine HCl administered over 24 hours is well tolerated in adults when used for postoperative pain management: ie, 2016 mg. Caution should be exercised when administering ropivacaine for prolonged periods of time, eg, greater than 70 hours in debilitated patients.
For treatment of postoperative pain, the following technique can be recommended: If regional anesthesia was not used intraoperatively, then an initial epidural block with 5 mL to 7 mL ropivacaine is induced via an epidural catheter. Analgesia is maintained with an infusion of ropivacaine HCl 2 mg/mL (0.2%). Clinical studies have demonstrated that infusion rates of 6 mL to 14 mL (12 mg to 28 mg) per hour provide adequate analgesia with nonprogressive motor block. With this technique a significant reduction in the need for opioids was demonstrated. Clinical experience supports the use of ropivacaine epidural infusions for up to 72 hours.
![Ropivacaine Hydrochloride Injection, Solution [Sagent Pharmaceuticals]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed31f0cc-0282-485a-8a1a-d11524de4411&name=rop00-0003-02.jpg)
![Ropivacaine Hydrochloride Injection, Solution [Hospira, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6276a39b-66ef-487d-b24b-d5f001755647&name=ropivacaine-hydrochloride-injection1-figure-2-jCA-3553F.jpg)
Login To Your Free Account